Rothschild cuts Moderna to Sell from Neutral, analyst note
Rothschild & Co analyst Simon Baker cut Moderna from Neutral to Sell in a research note Thursday, marking the company’s second Sell rating. The downgrade was described as having little link to commercial potential or pipeline prospects.
By Mackenzie TatananniModerna has received its second Sell rating on Wall Street, but the downgrade has little to do with the drugmaker's commercial potential or pipeline prospects.Rothschild & Co.
Redburn analyst Simon Baker cut Moderna to Sell from Neutral in a research note Thursday.
Although Ba…